How to Reconstitute MK-677 (Ibutamoren): Bacteriostatic Water vs Sterile Water

What Exactly Is MK-677 and Why Does Diluent Choice Matter?

MK-677 (Ibutamoren, developmental code L-163,191) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) secretion and raises insulin-like growth factor-1 (IGF-1) without suppressing cortisol or prolactin at therapeutic doses. In the landmark 2008 phase II trial by Nass et al. (N=65 older adults), MK-677 25 mg/day raised IGF-1 by 60.1% and increased GH pulse amplitude significantly compared with placebo over 12 months 1.

Oral vs. Injectable Presentations

Most clinical-trial and compounding pharmacy supply of MK-677 arrives as an oral capsule or sublingual tablet. Research-grade suppliers, however, frequently lyophilize MK-677 into a powder vial for subcutaneous or intramuscular delivery. When a vial of lyophilized powder is in hand, the diluent selection directly controls:

• Microbial safety across multiple draws from the same vial.
• Chemical stability of the reconstituted solution.
• Injection tolerability (pH and osmolality affect site pain).

The United States Pharmacopeia (USP) Chapter <797> sets compounding standards for sterility and beyond-use dating of reconstituted preparations 2.

Benzyl Alcohol as a Preservative

Bacteriostatic water for injection contains 0.9% benzyl alcohol as its antimicrobial agent. The FDA-approved labeling for bacteriostatic water for injection specifies that the solution is "for dilution or dissolution of drugs for intravenous, intramuscular, or subcutaneous injection" and may be reused from the same vial over multiple administrations 3. Benzyl alcohol concentrations at 0.9% achieve bacteriostatic (not bactericidal) suppression of common gram-positive and gram-negative contaminants.

Sterile water for injection carries no preservative. Once the vial seal is punctured, sterility degrades rapidly through particulate and microbial ingress. USP <797> classifies opened single-dose containers of sterile water as having a beyond-use time of 1 hour at room temperature or 24 hours refrigerated 2.

Bacteriostatic Water vs. Sterile Water: The Decision Table

Use bacteriostatic water when you plan more than one draw from a vial over days or weeks. Use sterile water only when the entire reconstituted volume will be administered in a single session.

When Bacteriostatic Water Wins

• Multi-dose vials drawn over 7 to 28 days.
• Research protocols calling for repeated subcutaneous injections.
• Any scenario where the vial will be stored refrigerated between doses.

Benzyl alcohol preservative activity has been validated in FDA-approved injectable products at 0.9% concentration for up to 28 days after first puncture when stored at 2 to 8 °C 3. Because most self-administered MK-677 protocols run 8 weeks or longer based on trial durations, a single reconstituted vial rarely lasts more than two to three weeks before the powder is exhausted, making bacteriostatic water the practical standard.

When Sterile Water Is Acceptable

• Single-administration research use where the full dose is drawn and injected immediately.
• Individuals with a documented allergy or sensitivity to benzyl alcohol. Published case literature links high-dose benzyl alcohol (not 0.9% preservative amounts) to "gasping syndrome" in neonates, and the FDA advises against benzyl-alcohol-containing products in premature infants 4.
• Situations where regulatory or institutional protocols prohibit multi-use vials.

pH and Osmolality Considerations

MK-677 lyophilized powder reconstitutes to a slightly acidic solution (estimated pH 4 to 5 based on its maleate salt form used in research). Bacteriostatic water for injection has a pH of 4.5 to 7.0 per USP specification. Sterile water for injection is pH 5.0 to 7.0. Neither diluent introduces a clinically significant pH mismatch for subcutaneous delivery, where tissue buffering capacity accommodates solutions in the pH 3 to 9 range 5.

Step-by-Step Reconstitution Protocol

These steps reflect aseptic technique consistent with USP <797> non-sterile-to-sterile compounding guidance and FDA recommendations for home-use injectables 2.

Materials Checklist

• MK-677 lyophilized powder vial (confirm labeled quantity, e.g., 10 mg or 25 mg).
• Bacteriostatic water for injection, multi-dose vial (or sterile water for injection, single-dose vial).
• Two 1 mL insulin syringes with 28 to 31 gauge needles (one to draw diluent, one to administer dose).
• 70% isopropyl alcohol swabs.
• Puncture-resistant sharps container.
• Refrigerator capable of holding 2 to 8 °C.

Reconstitution Steps

1. Wash hands for 20 seconds with soap and water. Dry completely.
2. Swab the rubber septum of both the powder vial and the diluent vial with a fresh alcohol swab. Allow 30 seconds to dry before needle puncture, residual alcohol can denature peptide bonds if introduced into the vial 6.
3. Draw the target volume of bacteriostatic water into the insulin syringe (see dosing calculator section below).
4. Insert the needle into the MK-677 vial at a 45-degree angle. Aim the stream of diluent at the glass wall of the vial rather than directly at the powder cake. Direct force on the powder accelerates aggregation.
5. Do not shake. Roll the vial gently between your palms for 20 to 30 seconds until the powder is fully dissolved and the solution is clear. MK-677 reconstitutes readily; cloudiness after 60 seconds of gentle rolling suggests powder damage or an incompatible diluent.
6. Visually inspect the solution. Discard if particulates are present or the solution is not clear.
7. Label the vial with the reconstitution date, concentration (mg/mL), and beyond-use date (reconstitution date plus 28 days for bacteriostatic water; reconstitution date plus 24 hours for sterile water).
8. Refrigerate at 2 to 8 °C. Do not freeze.

Why the Angle and Aim of Injection Matter

Protein and peptide lyophilates can denature at the air-liquid interface. Directing diluent at the vial wall, rather than the powder, reduces the mechanical disruption that promotes aggregation. This technique is consistent with manufacturer guidance for recombinant protein reconstitution and is endorsed by injectable biologics handling references 6.

MK-677 Dosing Calculator: Converting mg to Units

The most common source of dosing errors is unit confusion between milligrams and insulin-syringe units.

The Core Formula

Dose volume (mL) = Desired dose (mg) / Concentration (mg/mL)

Units on a U-100 insulin syringe = Dose volume (mL) x 100

Worked Examples

| Vial size | Diluent added | Concentration | Desired dose | Draw volume | Insulin syringe units | |-----------|--------------|---------------|--------------|-------------|----------------------| | 10 mg | 2 mL BAC water | 5 mg/mL | 12.5 mg | 0.25 mL | 25 units | | 10 mg | 2 mL BAC water | 5 mg/mL | 25 mg | 0.50 mL | 50 units | | 25 mg | 2 mL BAC water | 12.5 mg/mL | 12.5 mg | 0.10 mL | 10 units | | 25 mg | 5 mL BAC water | 5 mg/mL | 25 mg | 0.50 mL | 50 units |

The 2 mL per 10 mg standard (5 mg/mL) is the most broadly used convention in research-grade MK-677 protocols because it keeps draw volumes in the 0.25 to 0.50 mL range, which is comfortable on a 1 mL insulin syringe and minimizes measurement error. Smaller volumes (e.g., 0.05 mL for a 12.5 mg dose from a 25 mg/2 mL vial) push measurement uncertainty above 10% on a standard U-100 syringe, which is clinically unacceptable.

Diluent Volume and Concentration Tradeoffs

Adding more bacteriostatic water lowers concentration and makes small doses easier to measure accurately. Adding less diluent raises concentration, reduces injection volume (relevant for intramuscular comfort), and extends the number of days before the vial is exhausted. For daily subcutaneous dosing of 12.5 to 25 mg, a 5 mg/mL concentration (2 mL per 10 mg vial) offers the best balance of measurement accuracy and manageable injection volume.

Syringe Selection: Insulin Syringes and Injection Technique

A 1 mL U-100 insulin syringe with a 29 to 31 gauge, 5/16-inch (8 mm) needle is the standard choice for subcutaneous MK-677 injection. Gauge and needle length matter for tolerability and delivery precision.

Why Insulin Syringes Are Preferred

Insulin syringes have low dead-space needles, meaning minimal solution is trapped in the hub after injection. A standard luer-slip syringe can lose 0.05 to 0.15 mL of solution in dead space. At a concentration of 5 mg/mL, losing 0.10 mL equals 0.5 mg lost per injection, a 4% error on a 12.5 mg dose and negligible on a 25 mg dose, but worth eliminating with a low-dead-space design 7.

Gauge Selection

• 28 gauge: easier to draw viscous solutions; slightly more tissue trauma.
• 29 to 30 gauge: the clinical sweet spot for subcutaneous peptide injection.
• 31 gauge: minimal pain; may require slower aspiration.

The 2015 Endocrine Society Clinical Practice Guideline on growth hormone deficiency in adults specifies subcutaneous injection sites as the abdomen, thigh, or upper arm, rotating sites to prevent lipohypertrophy 8.

Subcutaneous vs. Intramuscular Delivery

MK-677 clinical trials (Nass 2008, Murphy 1998) used oral dosing exclusively 1 9. Subcutaneous injection of the reconstituted solution follows the same pharmacokinetic rationale as other growth hormone secretagogues: absorption from subcutaneous fat is predictable, and the 24-hour half-life means once-daily dosing covers GH pulsatility across sleep and waking hours regardless of the route 10.

Stability Data: How Long Does Reconstituted MK-677 Last?

Peptide stability after reconstitution depends on pH, temperature, light exposure, and preservative presence.

Refrigerated Storage (2 to 8 °C)

Bacteriostatic water suppresses microbial growth across a 28-day window per FDA labeling 3. Chemical degradation of MK-677 in aqueous solution has not been characterized in a peer-reviewed, publicly available stability study specific to this molecule. General peptide stability research published in the Journal of Pharmaceutical Sciences demonstrates that small non-peptide ghrelin mimetics with stable aromatic ring systems (which include ibutamoren's indole scaffold) show less hydrolytic degradation than linear peptide chains at refrigerated temperatures over 30-day windows 11.

Room Temperature: Avoid It

At room temperature (20 to 25 °C), microbial proliferation in reconstituted biologics accelerates significantly even in the presence of 0.9% benzyl alcohol when vials are repeatedly accessed. The CDC guidelines on safe injection practices specify that multi-dose vials should be stored at the temperature listed on the manufacturer label and discarded within 28 days of first use regardless of remaining volume 12.

Freeze-Thaw Cycles

Freezing reconstituted peptide solutions risks ice-crystal formation that disrupts molecular structure. Lyophilized (dry) MK-677 powder tolerates freezer storage; reconstituted solution does not. Keep reconstituted vials refrigerated, not frozen.

Clinical Context: What MK-677 Does in the Body

Understanding the pharmacology clarifies why dosing precision matters.

GH and IGF-1 Elevation

MK-677 binds the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, amplifying GH pulse amplitude without altering pulse frequency. In the Murphy et al. 1998 trial (N=32 healthy older adults), a single oral dose of MK-677 25 mg increased mean 24-hour GH area under the curve by 97% and IGF-1 by 52% compared with placebo 9.

Approved Indications and Investigational Status

MK-677 has no FDA-approved indication as of this writing. The FDA has not approved any ghrelin receptor agonist for clinical use in GH deficiency or body composition. Ibutamoren remains an investigational compound 13. Researchers at Eli Lilly and later Merck investigated it through phase II trials for GH deficiency, cachexia, and hip fracture recovery; none proceeded to NDA submission.

The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency in adults states: "We recommend against the use of GH secretagogues or GH-releasing peptides outside of approved clinical trials" 8.

Adverse Effects Relevant to Dosing

Dose-dependent adverse effects documented in clinical trials include transient increases in fasting glucose, insulin resistance, fluid retention (edema), and increased appetite. The Nass 2008 trial reported that fasting glucose increased by a mean of 0.3 mmol/L (5.4 mg/dL) and fasting insulin by 11% versus placebo at the 25 mg/day dose 1. These effects are dose-proportional, making accurate reconstitution and measured dosing more than a procedural formality.

Aseptic Technique: Common Errors and How to Avoid Them

Research-grade peptide users consistently make five preventable errors.

Error 1: Shaking the Vial

Agitation at the air-liquid interface denatures peptides by exposing hydrophobic regions to oxidizing air. Roll, never shake.

Error 2: Drawing Diluent Before Swabbing

Skin flora on unswiped septa can contaminate both the diluent vial and the peptide vial on the first draw. The CDC's injection safety guidelines require that septa be cleaned with 70% alcohol before every needle insertion 12.

Error 3: Reusing Needles

Needle bevel geometry degrades on first use. A used needle reinserted into a rubber septum introduces metal particulates into the vial. Use a fresh needle for every draw.

Error 4: Ignoring Beyond-Use Dates

Labeling a vial with only the reconstitution concentration and not the beyond-use date is a USP <797> violation in compounding pharmacy settings and a practical safety lapse in any setting 2.

Error 5: Storing at the Wrong Temperature

A vial left on a counter at 22 °C for 48 hours before refrigeration may already have microbial load exceeding the bacteriostatic threshold of 0.9% benzyl alcohol. Refrigerate immediately after reconstitution.

Reconstituting MK-677 for Oral vs. Injectable Use

A note on the more common presentation: if your MK-677 arrives as an oral capsule or liquid suspension, reconstitution is not required or applicable. Capsules are swallowed intact. Oral liquids supplied by compounding pharmacies are typically pre-dissolved in a carrier such as propylene glycol or medium-chain triglyceride oil and dosed by dropper.

The reconstitution protocol in this article applies exclusively to lyophilized powder vials intended for injection. Oral bioavailability of MK-677 is approximately 60 to 70% based on pharmacokinetic data from early Lilly studies, meaning the injected dose and the oral dose are not interchangeable milligram-for-milligram 10.